1. Introduction {#sec1-molecules-25-01772}
===============

*Xanthomonas oryzae* pv. *oryzae* and *Xanthomonas oryzae* pv. *oryzicola* parasitizing rice can cause serious degradation of rice quality and yield \[[@B1-molecules-25-01772]\]. *Xanthomonas axonopodis* pv. *citri* mainly harms citrus fruits while causing a plant bacterial disease, citrus canker \[[@B2-molecules-25-01772]\]. In recent decades, the long-term use of traditional bactericides has resulted in their large accumulation in the soil and resistance of pathogenic bacteria, reducing control capability. For example, bismerthiazol, one of the most widely used bactericides, has indicated low efficiency of 25.5% at a high dosage of 200 μg/mL \[[@B3-molecules-25-01772]\]. Therefore, it is necessary to develop highly efficient and environmentally friendly bactericides to protect crops. Thiazole-containing aromatic heterocycles are reported to bind to certain proteins and receptors of bacteria and exhibit a wide range of biological activities such as insecticidal \[[@B4-molecules-25-01772],[@B5-molecules-25-01772]\], bactericidal \[[@B6-molecules-25-01772],[@B7-molecules-25-01772],[@B8-molecules-25-01772]\], herbicidal \[[@B9-molecules-25-01772]\], antiviral \[[@B10-molecules-25-01772]\] and fungicidal ones \[[@B11-molecules-25-01772],[@B12-molecules-25-01772]\]. In addition, compounds with an amide structure have revealed various activities as antimicrobial \[[@B13-molecules-25-01772],[@B14-molecules-25-01772],[@B15-molecules-25-01772]\] and nematicidal \[[@B16-molecules-25-01772],[@B17-molecules-25-01772]\] agents. Based on the reported good performance of derivatives containing thiazole or amide groups, splicing them to get new antibacterial structures was presumed to be a reasonable and promising approach.

Attracted by these facts, we have carried out the preparation of a series of novel *N*-phenylacetamide derivatives **A**~1~--**A**~36~ and the subsequent evaluation of their biological activities against *Xoo*, *Xac* and *Xoc*. Their preliminary structure-activity relationships are discussed. Additionally, the nematicidal activity of all target compounds against *M. incognita* were also checked.

2. Results and Discussion {#sec2-molecules-25-01772}
=========================

2.1. Chemistry {#sec2dot1-molecules-25-01772}
--------------

As shown, compounds *N*-substituted-2-amino-4-arylthiazoles **A**~1~--**A**~36~ were synthesized following [Scheme 1](#molecules-25-01772-sch001){ref-type="scheme"}. Starting from *p*-phenylenediamine (PPD), the synthesis involves firstly aniline protection, amide formation and deprotection to afford the 4-amino-*N*-phenylacetamide intermediates **2** which were then turned into isothiocyanates **3** and converted to thioureas **4**. Finally, **4** were condensed with different α-halocarbonyl compounds to give the target derivatives. The steps for each reaction described in [Scheme 1](#molecules-25-01772-sch001){ref-type="scheme"} were elaborated as follows.

Specifically, the protection of PPD in first step utilized a *N*-tert-butyloxycarbonylation strategy \[[@B18-molecules-25-01772],[@B19-molecules-25-01772],[@B20-molecules-25-01772]\]. By reacting with 0.5 equiv. of di-*tert*-butyl dicarbonate (BOC~2~O) in dichloromethane (DCM), PPD was converted into the corresponding *N*-BOC-amine \[[@B20-molecules-25-01772]\]. The mono-*N*-BOC protected derivative (NH~2~-Ph-NH-BOC) **1** was purified by column chromatography to remove the di-*N*-BOC (BOC-NH-Ph-NH-BOC) side product. Then **1** was reacted with an acyl chloride (RCOCl) to produce the corresponding amide RCONH-Ph-NH-BOC, which was then acidified to produce the 4-amino-*N*-phenylacetamides **2**. Thereafter, **2** were converted to the corresponding isothiocyanates **3** via dithiocarbamates (generated by adding CS~2~ to Et~3~N) promoted by BOC~2~O and a catalytic amount of 4-dimethylaminopyridine (DMAP) \[[@B21-molecules-25-01772]\]. BOC~2~O here, as reported, may desulfurize the corresponding dithiocarbamates during the isothiocyanate formation \[[@B21-molecules-25-01772],[@B22-molecules-25-01772]\]. Then, various aryl thioureas **4** were prepared from isothiocyanates **3** upon reaction with ammonia \[[@B23-molecules-25-01772],[@B24-molecules-25-01772]\]. Finally, thioureas **4** were condensed with diverse α-bromophenylethanones \[[@B24-molecules-25-01772],[@B25-molecules-25-01772]\], synthesized separately via reaction of acetophenones with Br~2~ in DCM \[[@B24-molecules-25-01772]\], to afford the 2-amino-1,3-thiazole heterocyclic skeleton, and the targeted compound *N*-phenylacetamide derivatives containing thiazole moieties were thus obtained. The structures of all target compounds were confirmed by ^1^H-NMR, ^13^C-NMR and HRMS. Among them, it was unexpectedly found that compounds **A**~4~, **A**~7~, **A**~11~, **A**~12~ have been previously reported \[[@B25-molecules-25-01772]\].

2.2. In Vitro Antibacterial Activity {#sec2dot2-molecules-25-01772}
------------------------------------

The in vitro antibacterial activities of the target compounds against three phytopathogenic bacterial (*Xoo*, *Xac* and *Xoc*) were initially evaluated at the concentrations of 200 μg/mL and 100 μg/mL, respectively. As a comparison, the commercial bactericides bismerthiazol and thiodiazole copper served as positive controls (see preliminary screening results in the [Supplementary Materials](#app1-molecules-25-01772){ref-type="app"}).

Compounds that performed well in the initial tests were further tested to determine their EC~50~ values, with the results shown in [Table 1](#molecules-25-01772-t001){ref-type="table"}. The EC~50~ values of compounds **A**~1~, **A**~4~, **A**~6~ against *Xoo* are 156.7, 179.2, 144.7 µM, which were significantly better than that of thiodiazole copper (545.2 µM). Moreover, compound **A**~4~ had the best inhibitory effect on *Xoc* with an EC~50~ value of 194.9 µM, which was slightly better than that of bismerthiazol (254.96 µM) and thiodiazole copper (607.5 µM). Compound **A**~4~ (281.2 µM) showed the best antibacterial activity against *Xac*, which was better than that of the commercial bactericide thiodiazole copper (476.52 µM).

2.3. Structure-Activity Relationship Analyses {#sec2dot3-molecules-25-01772}
---------------------------------------------

With the results indicated in [Table 1](#molecules-25-01772-t001){ref-type="table"}, a preliminary structure-activity relationship of the target compounds can be discussed. It can be observed that the type and position of the substituent R on the benzene ring had an important effect on the bactericidal activity of the target compounds. First of all, the type and position of F, Cl, Br, and CF~3~ at the 4-position of the benzene ring can increase the bactericidal activity of the compound, and the 3-position is not conducive to improving the bactericidal activity. For example, the order of the inhibitory effect of the target compound on *Xoo* bacteria follows the order **A**~1~ \> **A**~2~, **A**~4~ \> **A**~5~, confirming the above conclusion. In addition, the activity trend **A**~1~ (4-F) \> **A**~4~ (4-Cl) \> **A**~7~ (4-Br) reveals that a 4-F substituted benzene ring is the most helpful for conferring antibacterial activity. Secondly, comparing different types of groups at the same position on the benzene ring, the corresponding compounds with 4-R electron-withdrawing substituents have a higher bactericidal activity against *Xoo*, *Xac* and *Xoc* than 4-R electron-donating substituents such as **A**~1~ (4-F) \> **A**~4~ (4-Cl) \> **A**~11~ (4-CH~3~). The type of amide-linked sidechain could also have a significant impact on the bactericidal activity of the corresponding target compounds.

2.4. Scanning Electron Microscopy Studies {#sec2dot4-molecules-25-01772}
-----------------------------------------

Due to its outstanding activity shown in [Table 1](#molecules-25-01772-t001){ref-type="table"}, compounds **A**~1~ was further examined by SEM analysis to study the effect on *Xoo*. It can be observed that the cell membrane was damaged by the compound and the normal physiological functions of the cell would thus be affected. More importantly, this adverse effect becomes more severe with increasing compound concentration. For example, the surface of cells without compound treatment is smooth and the cell membrane is intact ([Figure 1](#molecules-25-01772-f001){ref-type="fig"}A). At the concentration of 100 μg/mL, a small part of the cell morphology appears abnormal ([Figure 1](#molecules-25-01772-f001){ref-type="fig"}B). When the concentration was increased to 200 μg/mL, most of the cell surfaces were deformed, with few surviving cells ([Figure 1](#molecules-25-01772-f001){ref-type="fig"}C). In summary, the inhibitory effect of compound **A**~1~ on *Xoo* was further clarified by the SEM images.

2.5. Nematicidal Biological Activities {#sec2dot5-molecules-25-01772}
--------------------------------------

The nematicidal activity results of the target compounds are summarized in [Table 2](#molecules-25-01772-t002){ref-type="table"}. Unfortunately, most of the compounds showed poor activities against *M. incognita*, although compound **A**~23~, with its mortality rates of 100% at 500 μg/mL and 51.3% at 100 μg/mL which are comparable to the commercial nematicide avermectin (100% at 500 μg/mL and 71.8% at 100 μg/mL) in 24 h after treatment stuck out.

3. Experimental {#sec3-molecules-25-01772}
===============

3.1. Chemicals and Instruments {#sec3dot1-molecules-25-01772}
------------------------------

All reagents used for reactions were purchased from a commercial source (Aladdin Chemistry Co., Shanghai, China) and were of analytical grade with no further purification. Basic alumina oxide (200 to 300 mesh, Aladdin Chemistry Co.) was applied for purification of target compounds by column chromatography. Melting points of the target compounds were recorded on an XT-4B binocular microscope (Beijing Tech Instrument Co., Beijing, China). NMR spectra were obtained on a 400 MHz spectrometer (Bruker BioSpin AG, Fällanden, Switzerland) using TMS as internal standard and DMSO-*d~6~* as solvent. HRMS data were recorded on a Thermo Scientific Q Exactive system (Thermo Fisher Scientific, Waltham, MA, USA). Single crystal structure data were collected using a single crystal diffractometer (Gemini E, Oxford Instruments, Oxford, UK). SEM analysis was carried out with a FEI Nova NanoSEM 450 (FEI Company, Hillsboro, OR, USA).

3.2. General Synthetic Procedure for the Target Compounds {#sec3dot2-molecules-25-01772}
---------------------------------------------------------

### 3.2.1. Synthesis of Intermediate **1** {#sec3dot2dot1-molecules-25-01772}

*p*-Phenylenediamine (PPD, 9.25 mmol, 1.0 equiv.) was dissolved in dry dichloromethane (50mL), degassed under N~2~ (g) and cooled in an ice bath. BOC~2~O (4.62 mmol, 0.50 equiv.) was added dropwise to the *p*-phenylenediamine solution using a disposable syringe. After the addition, the mixture was reacted at room temperature (R.T.) for 5 h, monitored by thin layer chromatography (TLC). After the reaction was complete, the mixture was purified by flash column chromatography (petroleum ether:ethyl acetate, 3:1) to obtain yellow solid compound intermediate **1** in a yield of 63%.

### 3.2.2. Synthesis of Intermediates **2** {#sec3dot2dot2-molecules-25-01772}

A mixture of **1** (1.0 equiv.) and an acid chloride (1.10 equiv.) in DCM (40mL) was stirred at 0 °C for 1 h. Then, excess 4 M HCl was added and stirred at R.T. for 10 min. The reaction progress was monitored by TLC. After completion of the reaction, a saturated Na~2~CO~3~ solution was added to adjust to 7.0 the pH of mixture which was then extracted with DCM (50 mL × 3). The organic phase was concentrated to give intermediate **2** as white solids in yields of 69--75%.

### 3.2.3. Synthesis of Intermediates **3** {#sec3dot2dot3-molecules-25-01772}

A mixture of intermediate **2** (12.64 mmol, 1.0 equiv.), triethylamine (Et~3~N, 13.87 mmol, 1.10 equiv.) and carbon disulfide (CS~2,~ 126.40 mmol, 10.0 equiv) in ethanol (50 mL) was stirred at R.T. for 2 h, then cooled down to 0 °C to add DMAP (0.38 mmol, 0.03 equiv.) and BOC~2~O (12.51 mmol, 0.99 equiv.). The mixture was stirred for about 2 h at room temperature till the reactants were completely consumed. The mixture was cooled to −10 °C overnight then filtered to give the isothiocyanates **3** in yields of 75--81%.

### 3.2.4. Synthesis of the Intermediates **4** {#sec3dot2dot4-molecules-25-01772}

The mixture of **3** (12.64 mmol, 1.0 equiv.) with excess ammonia solution in ethanol (30 mL) was stirred at R.T. The reaction was monitored by TLC using petroleum ether:ethyl acetate (1:1). The mixture was filtered through a Celite pad to afford the thioureas **4** in approximately 100% yield.

### 3.2.5. Synthesis of the α-Bromophenylethanone Intermediates {#sec3dot2dot5-molecules-25-01772}

Br~2~ (2.2 mmol, 1.10 equiv.) was added slowly to a DCM solution of substituted acetophenone (2.0 mmol, 1.0 equiv.) and the mixture was stirred at R.T. for 5 h, after which the reaction mixture was tpoured into distilled water and extracted with DCM three times. The organic phases were combined and the solvent removed under reduced pressure to obtain the α-bromophenylethanones in yields of 65--83%.

### 3.2.6. Synthesis of the Target Compounds **A** {#sec3dot2dot6-molecules-25-01772}

A mixture of α-bromophenylethanone (2.05 mmol, 1.0 equiv.) and intermediate **4** (2.25 mmol, 1.10 equiv.) was dissolved in ethanol (20 mL) and then heated at reflux for 5 h. Upon completion of the reaction the liquid was filtered and the solid formed was washed with saturated potassium carbonate solution. The crude product was purified by column chromatography on basic alumina to give the various target compounds in yields ranging from 55% to 94%, respectively.

*N-(4-((4-(4-Fluorophenyl)thiazol-2-yl)amino)phenyl)acetamide* (**A**~1~): yellow solid; yield 57%; mp: 201.0--202.0 °C; ^1^H-NMR δ 10.19 (s, 1H), 9.85 (s, 1H), 7.96 (m, 2H, Ar-H), 7.63 (d, *J* = 8.9 Hz, 2H, Ar-H), 7.54 (d, *J* = 8.9 Hz, 2H, Ar-H), 7.27 (d, *J* = 8.5 Hz, 2H, Ar-H), 7.24 (s, 1H, thiazole-H), 2.03 (s, 3H, CH~3~). ^13^C-NMR δ 168.29, 163.84, 163.28, 160.85, 149.48, 137.11, 133.80, 131.65 (d, *J* = 2.9 Hz), 128.14 (d, *J* = 8.1 Hz), 120.35, 117.76, 116.05, 115.83, 102.72, 24.35. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~17~H~15~FN~3~OS: 328.09144; found: 328.09097.

*N-(4-((4-(3-Fluorophenyl)thiazol-2-yl)amino)phenyl)acetamide* (**A**~2~): yellow solid; yield 82%; mp: 162.4--163.2 °C; ^1^H-NMR δ 10.16 (s, 1H, NH), 9.81 (s, 1H,NH), 7.91 (d, *J* = 8.6 Hz, 2H, Ar-H), 7.59 (d, *J* = 9.0 Hz, 2H, Ar-H), 7.51 (d, *J* = 9.0 Hz, 2H, Ar-H), 7.45 (d, *J* = 8.6 Hz, 2H, Ar-H), 7.33 (s, 1H, thiazole-H), 1.99 (s, 3H, CH~3~). ^13^C-NMR δ 168.26, 163.65, 150.60, 137.22 (d, *J* = 4.8 Hz), 133.71, 132.41, 129.67, 126.10, 120.35, 117.70, 102.07, 24.35, 21.33. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~17~H~15~FN~3~OS: 328.09144; found: 328.09094.

*N-(4-(4-(3,4-Difluorophenyl)thiazol-2-ylamino)phenyl)acetamide* (**A**~3~): yellow solid; yield 81%; mp: 228.8--229.3 °C; ^1^H-NMR δ 10.21 (s, 1H), 9.85 (s, 1H), 7.91--7.87 (m, 1H, Ar-H), 7.77--7.72 (m, 1H, Ar-H), 7.59 (d, *J* = 9.0 Hz, 2H, Ar-H), 7.52 (d, *J* = 9.0 Hz, 2H, Ar-H), 7.45 (d, *J* = 10.6 Hz, 1H, Ar-H), 7.36 (s, 1H, thiazole-H), 2.00 (s, 3H, CH~3~). ^13^C-NMR δ 168.2, 163.98, 148.82, 137.29, 136.99, 133.94, 131.35, 130.62, 128.56, 125.16, 122.56, 120.37, 117.91, 104.64, 24.35. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~17~H~14~F~2~N~3~OS: 346.08202; found: 346.08136.

*N-(4-(4-(4-Chlorophenyl)thiazol-2-ylamino)phenyl)acetamide* (**A**~4~): yellow solid; yield 87%; mp: 210.5--211.2 °C; ^1^H-NMR δ 10.16 (s, 1H, NH), 9.81 (s, 1H, NH), 7.93--7.88 (m, 2H, Ar-H), 7.59 (d, *J* = 9.0 Hz, 2H, Ar-H), 7.51 (d, *J* = 8.6 Hz, 2H, Ar-H), 7.45 (d, *J* = 8.6 Hz, 2H, Ar-H), 7.33 (s, 1H, thiazole-H), 1.99 (s, 3H, CH~3~). ^13^C-NMR δ 168.34, 163.98, 149.37, 137.12, 133.94, 132.43, 129.19, 127.93, 120.41, 117.89, 103.90, 24.42. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~17~H~15~ClN~3~OS: 344.06189; found: 344.06134.

*N-(4-(3-(4-Chlorophenyl)thiazol-2-ylamino)phenyl)acetamide* (**A**~5~): yellow solid; yield 88%; mp: 179.7--180.3 °C; ^1^H-NMR δ 10.22 (s, 1H, NH), 9.86 (s, 1H, NH), 7.78 (d, *J* = 7.9 Hz, 1H, Ar-H), 7.71 (d, *J* = 9.8 Hz, 1H, Ar-H), 7.65--7.59 (m, 2H, Ar-H), 7.55 (d, *J* = 9.0 Hz, 2H, Ar-H), 7.48 (d, *J* = 6.2 Hz, 1H, Ar-H), 7.44 (s, 1H, thiazole-H), 7.14 (d, *J* = 2.5 Hz, 1H, Ar-H), 2.03 (s, 3H, CH~3~). ^13^C-NMR δ 168.35, 163.90, 148.71, 137.31, 137.03, 133.93, 131.37, 130.58, 128.51, 125.15, 122.55, 120.28, 117.79, 104.70, 24.34. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~17~H~15~ClN~3~OS: 344.06189; found: 344.06140.

*N-(4-((4-(3,4-Dichlorophenyl)thiazol-2-yl)amino)phenyl)acetamide* (**A**~6~): yellow solid; yield 93%; mp: 179.3--181.7 °C; ^1^H-NMR δ 10.55 (s, 1H, NH), 10.15 (s, 1H, NH), 8.14 (d, *J* = 2.0 Hz, 1H, Ar-H), 7.93 (m, 1H, Ar-H), 7.70 (d, *J* = 8.5 Hz, 1H, Ar-H), 7.67 (d, *J* = 9.1 Hz, 2H, Ar-H), 7.61 (d, *J* = 9.1 Hz, 2H, Ar-H), 7.54 (s, 1H, thiazole-H), 2.06 (s, 3H, CH~3~). ^13^C-NMR δ 168.37, 164.00, 147.82, 136.97, 135.60, 133.99, 131.86, 131.37, 130.05, 127.58, 126.30, 120.26, 117.80, 105.37, 24.34. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~17~H~14~Cl~2~N~3~OS: 378.02291; found: 378.02249.

*N-(4-((4-(4-Bromophenyl)thiazol-2-yl)amino)phenyl)acetamide* (**A**~7~): white solid; yield 75%; mp: 209.6--210.4 °C; ^1^H-NMR δ 10.19 (s, 1H, NH), 9.83 (s, 1H, NH), 7.84 (m, 2H, Ar-H), 7.60 (d, *J* = 9.1 Hz, 2H, Ar-H), 7.58 (d, *J* = 4.4 Hz, 2H, Ar-H), 7.52 (d, *J* = 8.8 Hz, 2H, Ar-H), 7.33 (s, 1H, thiazole-H), 2.00 (s, 3H, CH~3~). ^13^C-NMR δ 168.36, 163.96, 149.40, 137.11, 134.27, 133.91, 132.10, 128.24, 121.04, 120.40, 117.87, 103.98, 24.43. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~17~H~15~BrN~3~OS: 388.01137; found: 388.01102.

*N-(4-((4-(3-Bromophenyl)thiazol-2-yl)amino)phenyl)acetamide* (**A**~8~): yellow solid; yield 85%; mp: 202.8--203.9 °C; ^1^H-NMR δ 10.38 (s, 1H, NH), 10.01 (s, 1H, NH), 8.04 (t, *J* = 1.8 Hz, 1H, Ar-H), 7.90 (d, *J* = 7.9 Hz, 1H, Ar-H), 7.62-7.57 (m, 2H, Ar-H), 7.56-7.52 (m, 2H, Ar-H), 7.46 (d, *J* = 6.9 Hz, 1H, Ar-H), 7.42 (s, 1H, thiazole-H), 7.36 (t, *J* = 7.9 Hz, 1H, Ar-H), 2.00 (s, 3H,CH~3~). ^13^C-NMR δ 168.29, 163.98, 148.82, 137.29, 136.99, 133.94, 131.35, 130.62, 128.56, 125.16, 122.56, 120.37, 117.91, 104.64, 24.35. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~17~H~15~BrN~3~OS: 388.01137; found: 388.01102.

*N-(4-(4-(4-(Trifluoromethyl)phenyl)thiazol-2-ylamino)phenyl)acetamide* (**A**~9~): yellow solid; yield 69%; mp: 253.2--254.2 °C; ^1^H-NMR δ 10.29 (s, 1H, NH), 9.89 (s, 1H, NH), 8.14 (d, *J* = 8.3 Hz, 2H, Ar-H), 7.73-7.79 (d, *J* = 7.8 Hz, 2H, Ar-H), 7.65 (m, 2H, Ar-H), 7.58 (d, *J* = 2.2 Hz, 2H, Ar-H), 7.56 (s, 1H, thiazole-H), 2.04 (s, 3H, CH~3~). ^13^C-NMR δ 168.30, 164.01, 148.99, 138.67, 136.97, 133.93, 128.14, 127.82, 126.87, 126.38 (d, *J* = 59.5 Hz), 123.50, 120.30, 117.85, 105.87, 24.36. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~18~H~15~F~3~N~3~OS: 378.08824; found: 378.08765.

*N-(4-((4-(3-(Trifluoromethyl)phenyl)thiazol-2-yl)amino)phenyl)acetamide* (**A**~10~): yellow solid; yield 87%; mp: 179.3--180.7 °C; ^1^H-NMR δ 10.31 (s, 1H, NH), 9.93 (s, 1H,NH), 8.26 (d, *J* = 11.0 Hz, 2H, Ar-H), 7.69 (d, *J* = 6.9 Hz, 2H, Ar-H), 7.67--7.62 (m, 2H, Ar-H), 7.60 (d, *J* = 9.1 Hz, 2H, Ar-H), 7.58 (s, 1H, thiazole-H), 2.07 (s, 3H, CH~3~). ^13^C-NMR δ 168.39, 164.18, 148.81, 136.98, 135.88, 133.98, 130.06 (d, *J* = 33.3Hz), 129.52, 128.79, 126.09, 124.38 (d, *J* = 3.6 Hz), 123.38, 122.35 (d, *J* = 3.7 Hz), 120.38, 117.97, 104.95, 24.32. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~17~H~15~F~3~N~3~OS: 378.08824; found: 378.08765.

*N-(4-(4-p-Tolylthiazol-2-ylamino)phenyl)acetamide* (**A**~11~): yellow solid; yield 89%; mp: 207.2--208.1 °C; ^1^H-NMR δ 10.15 (s, 1H, NH), 9.85 (s, 1H, NH), 7.81 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.63 (d, *J* = 8.9 Hz, 2H, Ar-H), 7.54 (d, *J* = 8.9 Hz, 2H, Ar-H), 7.23 (d, *J* = 8.1 Hz, 2H, Ar-H), 7.21 (s, 1H), 2.33 (s, 3H, CH~3~), 2.03 (s, 3H, CH~3~). ^13^C-NMR δ 168.26, 163.66, 150.61, 137.23, 133.72, 132.41, 129.67, 126.10, 120.36, 117.71, 102.06, 24.35, 21.32; HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~18~H~18~N~3~OS: 324.11651; found: 324.11597.

*N-(4-((4-Phenylthiazol-2-yl)amino)phenyl)acetamide* (**A**~12~): yellow solid; yield 71%; mp: 174.7--175.2 °C; ^1^H-NMR δ 10.19 (s, 1H, NH), 9.88 (s, 1H, NH), 7.9--7.86 (m, 2H, Ar-H), 7.66 (d, *J* = 9.0 Hz, 2H, Ar-H), 7.57 (d, *J* = 9.0 Hz, 2H, Ar-H), 7.43 (t, *J* = 7.6 Hz, 2H, Ar-H), 7.31 (t, *J* = 7.3 Hz, 1H, Ar-H), 7.27 (s, 1H, thiazole-H), 2.04 (s, 3H, CH~3~). ^13^C-NMR δ 168.38, 163.79, 150.57, 137.22, 135.03, 133.74, 129.11, 128.01, 126.15, 120.44, 117.76, 102.97, 24.32. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~17~H~16~N~3~OS: 310.10086; found: 310.10034.

*N-(4-((4-(4-Fluorophenyl)thiazol-2-yl)amino)phenyl)propionamide* (**A**~13~): white solid; yield 85%; mp: 186.5--187.4 °C; ^1^H-NMR δ 10.24 (s, 1H, NH), 9.80 (s, 1H, NH), 7.95 (s, 1H, thiazole-H), 7.93--7.87 (m, 1H, Ar-H), 7.64--7.60 (m, 2H, Ar-H),7.60--7.54 (m, 2H, Ar-H), 7.50--7.41 (m, 2H, Ar-H), 7.37 (dd, *J* = 5.9, 0.9 Hz, 1H), 2.31 (q, *J* = 7.6 Hz, 2H, CH~2~), 1.10 (t, *J* = 7.6 Hz, 3H, CH~3~). ^13^C-NMR δ 172.03, 164.03, 148.82, 137.30, 136.93, 134.00, 131.34, 130.62, 128.58, 125.14, 122.55, 120.41, 117.95, 104.62, 29.91, 10.25. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~18~H~17~FN~3~OS: 342.10709; found: 342.10617.

*N-(4-((4-(3-Fluorophenyl)thiazol-2-yl)amino)phenyl)propionamide* (**A**~14~): white solid; yield 83%; mp: 230.2--231.1 °C; ^1^H-NMR δ 10.18 (s, 1H, NH), 9.76 (s, 1H, NH), 7.74 (d, *J* = 7.8 Hz, 1H, Ar-H), 7.67 (d, *J* = 10.6 Hz, 1H, Ar-H), 7.59 (d, *J* = 8.8 Hz, 2H, Ar-H), 7.54 (d, *J* = 8.9 Hz, 2H,Ar-H), 7.44 (dd, *J* = 14.3, 7.8 Hz, 1H, Ar-H), 7.39 (s, 1H, thiazole-H), 7.11 (dd, *J* = 11.7, 5.4 Hz, 1H, Ar-H), 2.27 (q, *J* = 7.5 Hz, 2H, CH~2~), 1.06 (t, *J* = 7.5 Hz, 3H, CH~3~). ^13^C-NMR δ 172.04, 164.21, 163.89, 161.80, 149.24, 137.40, 136.95, 133.91, 131.13, 122.23, 120.41, 117.86, 114.77, 112.48, 104.53, 29.90, 10.27. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~18~H~17~FN~3~OS: 342.10709; found: 342.10617.

*N-(4-((4-(3,4-Difluorophenyl)thiazol-2-yl)amino)phenyl)propionamide* (**A**~15~): white solid; yield 69%; mp: 230.4--230.8 °C; ^1^H-NMR δ 10.18 (s, 1H, NH), 9.75 (s, 1H, NH), 7.92-7.87 (m, 1H, Ar-H), 7.75 (dd, 1H, *J* = 8.6, 4.3 Hz, Ar-H), 7.61-7.56 (m, 2H, Ar-H), 7.53 (dd, *J* = 9.2, 2.3 Hz, 2H, Ar- H), 7.46 (d, *J* = 10.6, 1H, Ar-H), 7.37 (s, 1H, thiazole-H), 2.27 (q, *J* = 7.6 Hz, 2H, CH~2~), 1.05 (t, *J* = 7.6 Hz, 3H, CH~3~). ^13^C-NMR δ 172.00, 164.00, 148.37, 136.89, 133.96, 122.92, 120.39, 118.24 (d, *J* = 17.2 Hz), 117.89, 114.87 (d, *J* = 18.4 Hz), 104.16, 29.90, 10.27. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~18~H~16~F~2~N~3~OS: 360.09767; found: 360.09653.

*N-(4-((4-(4-Chlorophenyl)thiazol-2-yl)amino)phenyl)propionamide* (**A**~16~): white solid; yield 90%; mp: 269.3--270.1 °C; ^1^H-NMR δ 10.24 (s, 1H, NH), 9.80 (s, 1H, NH), 7.97--7.84 (m, 2H, Ar-H), 7.62 (d, *J* = 9.2 Hz, 2H, Ar-H), 7.58 (d, *J* = 9.2 Hz, 2H, Ar-H), 7.50--7.42 (m, 2H, Ar-H), 7.33 (s, 1H, thiazole-H), 2.21 (q, *J* = 7.6 Hz, 2H, CH~2~), 1.05 (t, *J* = 7.6 Hz, 3H, CH~3~). ^13^C-NMR δ 172.07, 163.93, 149.32, 137.03, 133.94, 132.41, 129.20, 127.92, 120.38, 117.84, 103.90, 29.96, 10.36. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~18~H~17~ClN~3~OS: 358.07754; found: 358.07639.

*N-(4-((4-(3-Chlorophenyl)thiazol-2-yl)amino)phenyl)propionamide* (**A**~17~): white solid; yield 82%; mp: 223.5--224.6 °C; ^1^H-NMR) δ 10.24 (s, 1H, NH), 9.80 (s, 1H, NH), 7.95 (s, 1H, thiazole-H), 7.90 (d, *J* = 7.8 Hz, 1H, Ar-H), 7.62 (d, *J* = 9.2 Hz, 2H, Ar-H), 7.58 (d, *J* = 9.2 Hz, 2H, Ar-H), 7.52--7.42 (m, 2H, Ar-H), 7.37 (dd, *J* = 8.0, 1.1 Hz, 1H, Ar-H), 2.31 (q, *J* = 7.6 Hz, 2H, CH2), 1.10 (t, *J* = 7.6 Hz, 3H, CH3). ^13^C-NMR δ 172.08, 164.05, 149.00, 137.05, 134.02, 131.13, 127.80, 125.74, 124.84, 120.46, 117.97, 104.70, 29.97, 10.34. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~18~H~17~ClN3OS: 358.07754; found: 358.07639.

*N-(4-((4-(3,4-Dichlorophenyl)thiazol-2-yl)amino)phenyl)propionamide* (**A**~18~): white solid; yield 77%; mp: 258.1--259.0 °C; ^1^H-NMR δ 10.27 (s, 1H, NH), 9.80 (s, 1H, NH), 8.10 (d, *J* = 2.0 Hz, 1H, Ar-H), 7.88 (dd, *J* = 8.4, 2.1 Hz, 1H, Ar-H), 7.66 (d, *J* = 8.5 Hz, 1H, Ar-H), 7.57 (d, *J* = 9.2 Hz, 2H, Ar-H), 7.54 (d, *J* = 9.2 Hz, 2H, Ar-H), 7.50 (s, 1H, thiazole-H), 2.27 (q, *J* = 7.5 Hz, 2H, CH~2~), 1.05 (t, *J* = 7.6 Hz, 3H, CH~3~). ^13^C-NMR δ 172.12, 164.15, 147.98, 136.92, 135.65, 134.11, 131.95, 131.44, 130.17, 127.68, 126.36, 120.41, 118.01, 105.37, 29.96, 10.34. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~18~H~16~Cl~2~N~3~OS: 392.03856; found: 392.03856 392.03784.

*N-(4-(4-(4-Bromophenyl)thiazol-2-ylamino)phenyl)propionamide* (**A**~19~): white solid; yield 65%; mp: 219.5--220.8 °C; ^1^H-NMR δ 10.17 (s, 1H, NH), 9.75 (s, 1H, NH), 7.84 (d, *J* = 8.5 Hz, 2H,), 7.61--7.58 (m, 2H), 7.58 (d, *J* = 2.0 Hz, 2H, Ar-H), 7.53 (d, *J* = 9.0 Hz, 2H, Ar-H), 7.34 (s, 1H, thiazole-H), 2.27 (q, *J* = 7.6 Hz, 2H, CH~2~), 1.05 (t, *J* = 7.6 Hz, 3H, CH~3~). ^13^C-NMR δ 172.07, 163.99, 149.39, 137.03, 134.28, 133.97, 132.10, 128.24, 121.03, 120.41, 117.89, 103.98, 29.97, 10.34. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~18~H~17~BrN~3~OS: 402.02702; found: 402.02594.

*N-(4-(4-(3-Bromophenyl)thiazol-2-ylamino)phenyl)propionamide* (**A**~20~): white solid; yield 94%; mp: 238.4--239.1 °C; ^1^H-NMR δ 10.21 (s, 1H, NH), 9.79 (s, 1H, NH), 8.08 (t, *J* = 1.7 Hz, 1H, Ar-H), 7.93 (d, *J* = 7.8 Hz, 1H, Ar-H), 7.61 (d, *J* = 9.2 Hz, 2H, Ar-H), 7.57 (d, *J* = 9.2 Hz, 2H, Ar-H), 7.50 (dd, *J* = 8.0, 0.9 Hz, 1H, Ar-H), 7.45 (s, 1H, thiazole-H), 7.40 (t, J = 7.9 Hz, 1H, Ar-H), 2.31 (q, J = 7.5 Hz, 2H, CH~2~), 1.09 (t, *J* = 7.6 Hz, 3H, CH~3~). ^13^C-NMR δ 172.06, 164.02, 148.81, 137.29, 136.93, 133.98, 131.35, 130.62, 128.57, 125.13, 122.56, 120.41, 117.94, 104.62, 40.58, 40.37, 40.16, 39.95, 39.75, 39.54, 39.33, 29.91, 10.26. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~18~H~17~BrN~3~OS: 402.02702; found: 402.02606.

*N-(4-((4-(4-(Trifluoromethyl)phenyl)thiazol-2-yl)amino)phenyl)propionamide* (**A**~21~): white solid; yield 82%; mp: 242.1--243.0 °C; ^1^H-NMR δ 10.23 (s, 1H, NH), 9.76 (s, 1H, NH), 8.22--8.16 (m, 2H, Ar-H), 7.64 (d, *J* = 5.9 Hz, 2H, Ar-H), 7.60-7.55 (m, 2H, Ar-H), 7.54 (d, *J* = 2.9 Hz, 2H, Ar-H), 7.53 (s, 1H, thiazole-H), 2.27 (q, *J* = 7.5 Hz, 2H, CH~2~), 1.05 (t, *J* = 7.6 Hz, 3H, CH~3~). ^13^C-NMR δ 172.02, 164.18, 148.80, 136.87, 135.90, 134.07, 130.07 (d, 17.6 Hz), 126.10, 124.37, 123.39, 122.35, 120.3, 117.98, 104.97, 29.90, 10.25. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~19~H~17~F~3~N~3~OS: 392.10389; found: 392.10281.

*N-(4-((4-(3-(Trifluoromethyl)phenyl)thiazol-2-yl)amino)phenyl)isobutyramide* (**A**~22~): yellow solid; yield 86%; mp: 168.2--168.9 °C; ^1^H-NMR δ 10.24 (s, 1H, NH), 9.77 (s, 1H, NH), 8.21-8.17 (m, 2H, Ar-H), 7.64 (d, *J* = 7.1 Hz, 2H), 7.58 (d, *J* = 9.1 Hz, 2H, Ar-H), 7.55 (d, *J* = 2.3 Hz, 2H, Ar-H), 7.53 (s, 1H, thiazole-H), 2.27 (q, *J* = 7.5 Hz, 2H, CH~2~), 1.05 (t, *J* = 7.6 Hz, 3H, CH~3~). ^13^C-NMR δ 172.02, 164.18, 148.80, 136.87, 135.90, 134.07, 130.33, 129.97, 126.10, 124.37, 123.39, 122.35, 120.35, 117.98, 104.97, 29.90, 10.25. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~19~H~16~F~3~N~3~OS: 392.10389; found: 392.10266.

*N-(4-((4-(p-Tolyl)thiazol-2-yl)amino)phenyl)propionamide* (**A**~23~): white solid; yield 79%; mp: 286.4--287.5 °C; ^1^H-NMR (400 MHz, DMSO-*d~6~*) δ 10.23 (s, 1H, NH), 9.85 (s, 1H, NH), 7.81 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.66 (d, *J* = 9.0 Hz, 2H, Ar-H), 7.59 (d, *J* = 9.0 Hz, 2H, Ar-H), 7.24 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.21 (s, 1H, Thiazole-H), 2.34 (d, *J* = 8.1 Hz, 3H, CH~3~), 2.30 (d, *J* = 7.5 Hz, 2H, CH~2~), 1.10 (t, *J* = 7.6 Hz, 3H, CH~3~). ^13^C-NMR (100 MHz, DMSO-*d~6~*) δ 172.01, 163.67, 150.59, 137.19, 133.78, 132.42, 129.67, 126.09, 120.36, 117.70, 102.04, 29.91, 21.32, 10.30. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~19~H~20~N~3~OS: 338.13216; found: 338.13129.

*N-(4-((4-Phenylthiazol-2-yl)amino)phenyl)propionamide* (**A**~24~): white solid; yield 87%; mp: 187.5--187.9 °C; ^1^H-NMR δ 10.16 (s, 1H, NH), 9.76 (s, 1H, NH), 7.89 (dd, *J* = 8.2, 1.1 Hz, 2H, Ar-H), 7.61 (d, *J* = 9.0 Hz, 2H, Ar-H), 7.54 (d, *J* = 9.0 Hz, 2H, Ar-H), 7.39 (d, *J* = 7.7 Hz, 2H, Ar-H), 7.28 (dd, *J* = 10.5, 4.3 Hz, 1H, Ar-H), 7.26 (s, 1H, thiazole-H), 2.28 (q, *J* = 7.5 Hz, 2H, CH~2~), 1.06 (t, *J* = 7.6 Hz, 3H, CH~3~). ^13^C-NMR δ 171.99, 163.78, 150.55, 137.11, 135.04, 133.82, 129.11, 128.00, 126.15, 120.39, 117.76, 102.98, 29.91, 10.28. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~18~H~20~N~3~OS: 324.11651; found: 324.11514.

*N-(4-(4-(4-Fluorophenyl)thiazol-2-ylamino)phenyl)isobutyramide* (**A**~25~): yellow solid; yield 74%; mp: 172.4--173.9 °C; ^1^H-NMR δ 10.16 (s, 1H, NH), 9.72 (s, 1H, NH), 7.92 (m, 2H, Ar-H), 7.62--7.57 (m, 2H, Ar-H), 7.56--7.51 (m, 2H, Ar-H), 7.23 (d, *J* = 4.4 Hz, 2H, Ar-H), 7.20 (s, 1H, thiazole-H), 2.59--2.50 (m, 1H), 1.07 (d, *J* = 6.8 Hz, 6H, CH~3~). ^13^C-NMR δ 175.27, 163.94, 163.29, 160.86, 149.50, 137.08, 133.91, 131.67 (d, *J* = 3.1 Hz), 128.13 (d, *J* = 8.0 Hz), 120.53, 117.81, 116.03, 115.81, 102.70, 56.51, 35.30, 20.04. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~19~H~19~FN~3~OS: 356.12274; found: 356.12180.

*N-(4-((4-(3-Fluorophenyl)thiazol-2-yl)amino)phenyl)isobutyramide* (**A**~26~): yellow solid; yield 58%; mp: 230.9--232.0 °C; ^1^H-NMR δ 10.18 (s, 1H, NH), 9.72 (s, 1H, NH), 7.74 (d, *J* = 7.9 Hz, 1H, Ar-H), 7.67 (d, *J* = 9.8 Hz, 1H, Ar -H), 7.62--7.56 (m, 2H, Ar -H), 7.57--7.52 (m, 2H, Ar -H),, 7.44 (m, 1H, Ar-H), 7.40 (s, 1H, thiazole-H), 7.10 (m, 1H, Ar-H), 2.54 (m, 1H, CH), 1.07 (d, *J* = 6.8 Hz, 6H, CH~3~). ^13^C-NMR δ 175.24, 164.21, 163.91, 161.81, 149.25 (d, *J* = 2.8 Hz), 137.41 (d, *J* = 8.2 Hz), 136.98, 133.98, 131.13 (d, *J* = 8.5 Hz), 122.23, 120.54, 117.87, 114.66 (d, *J* = 21.3 Hz), 112.72, 112.49, 104.52, 35.29, 20.05. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~19~H~19~FN~3~OS: 356. 12274; found: 356 12149.

*N-(4-((4-(3,4-Difluorophenyl)thiazol-2-yl)amino)phenyl)isobutyramide* (**A**~27~): yellow solid; yield 69%; mp: 190.6--191.6 °C; ^1^H-NMR δ 10.22 (s, 1H, NH), 9.76 (s, 1H, NH), 7.93 (dd, *J* = 11.2, 6.9 Hz, 1H, Ar-H), 7.78 (dd, *J* = 8.7, 4.3 Hz, 1H, Ar-H), 7.61 (d, *J* = 9.3 Hz, 2H, Ar-H), 7.57 (d, *J* = 9.3 Hz, 2H, Ar-H), 7.50 (d, *J* = 8.6 Hz, 1H, Ar-H), 7.41 (s, 1H, thiazole-H), 2.59 (m, 1H, CH), 1.10 (d, *J* = 6.8 Hz, 6H, CH~3~). ^13^C-NMR δ 175.31, 164.06, 151.24, 150.45, 148.87 (d, *J* = 12.7 Hz), 148.36, 148.06 (d, *J* = 12.7 Hz), 136.95, 133.99, 132.71, 122.89, 120.57, 118.22 (d, *J* = 17.1 Hz), 117.92, 114.86 (d, *J* = 18.3 Hz), 104.13, 35.29, 20.03. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~19~H~18~N~3~OF~2~S: 374.11332; found: 374.11191.

*N-(4-((4-(4-Chlorophenyl)thiazol-2-yl)amino)phenyl)isobutyramide* (**A**~28~): yellow solid; yield 91%; mp: 264.5--265.7 °C; ^1^H-NMR δ 10.15 (s, 1H, NH), 9.72 (s,1H, NH), 7.88 (m, 2H, Ar-H) 7.65-7.57 (m, 2H, Ar-H), 7.57--7.52 (m, 2H, Ar-H), 7.40 (m, 2H, Ar-H), 7.28 (d, *J* = 7.3 Hz, 1H, Ar-H), 7.26 (s, 1H, thiazole-H), 2.60--2.49 (m, 1H, CH), 1.11 (d, *J* = 6.8 Hz, 6H, CH~3~). ^13^C-NMR δ 175.28, 163.92, 149.22, 137.04, 133.92, 132.33, 129.12, 127.84, 120.43, 117.77, 103.83, 35.30, 20.07. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~19~H~19~ClN~3~OS: 372.09319; found: 372.09207.

*N-(4-((4-(3-Chlorophenyl)thiazol-2-yl)amino)phenyl)isobutyramide* (**A**~29~): yellow solid; yield 91%; mp: 234.4--235.7 °C; ^1^H-NMR δ 10.20 (s, 1H, NH), 9.73 (s, 1H, NH), 7.91 (t, *J* = 1.8 Hz, 1H, Ar-H), 7.86 (dd, *J* = 7.8, 0.9 Hz, 1H, Ar-H), 7.61--7.56 (m, 2H, Ar-H), 7.56--7.52 (m, 2H, Ar-H), 7.46--7.39 (m, 2H, Ar-H), 7.33 (dd, *J* = 8.0, 1.1 Hz, 1H, thiazole-H), 2.55 (m, 1H,CH), 1.07 (d, *J* = 6.8 Hz, 6H,CH~3~). ^13^C-NMR δ 175.25, 163.99, 148.93, 136.99, 133.98, 131.05, 127.73, 125.69, 124.76, 120.51, 117.90, 104.64, 35.30, 20.06. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~19~H~19~ClN~3~OS: 372.09319; found: 372.09204.

*N-(4-((4-(3,4-Dichlorophenyl)thiazol-2-yl)amino)phenyl)isobutyramide* (**A**~30~): yellow solid; yield 71%; mp: 251.4--252.7 °C; ^1^H-NMR δ 10.21 (s, 1H, NH), 9.72 (s, 1H, NH), 8.10 (d, *J* = 1.9 Hz, 1H, Ar-H), 7.88 (m,1H, Ar-H), 7.65 (m, 1H, Ar-H), 7.55 (d, *J* = 9.7 Hz, Ar-H), 7.55--7.51 (m, 2H, Ar-H), 7.49 (s, 1H, thiazole-H), 2.54 (m, 1H, CH), 1.07 (d, *J* = 6.8 Hz, 6H). ^13^C-NMR δ 175.25, 164.11, 147.93, 136.84, 135.57, 134.09, 131.89, 131.39, 130.13, 127.63, 126.30, 120.49, 117.96, 105.31, 35.29, 20.05. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~19~H~18~Cl~2~N~3~OS: 406.05421; found: 406.05307.

*N-(4-(4-(4-Bromophenyl)thiazol-2-ylamino)phenyl)isobutyramide* (**A**~31~): white solid; yield 87%; mp: 190.6--191.6 °C; ^1^H-NMR δ 10.19 (s, 1H, NH), 9.73 (s, 1H, NH), 7.92--7.82 (m, 2H, Ar-H), 7.66--7.60 (m, 4H, Ar-H), 7.57 (d, *J* = 9.2 Hz, 2H, Ar-H), 7.37 (s, 1H, thiazole-H), 2.65--2.53 (m, 1H, CH), 1.11 (d, *J* = 6.8 Hz, 6H, CH~3~). ^13^C-NMR δ 175.24, 163.98, 149.34, 137.00, 134.23, 133.97, 132.03, 128.17, 120.97, 120.50, 117.86, 103.91, 35.30, 20.05. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~19~H~19~BrN~3~OS: 416.04267; found: 416.04153.

*N-(4-(4-(3-Bromophenyl)thiazol-2-ylamino)phenyl)isobutyramide* (**A**~32~)**:** white solid; yield 55%; mp: 238.2--239.0 °C; ^1^H-NMR δ 10.17 (s, 1H, NH), 9.70 (s, 1H, NH), 8.05 (d, *J* = 1.8 Hz, 1H, Ar-H), 7.90 (dd, *J* = 6.6, 1.2 Hz, 1H, Ar-H), 7.56 (d, *J* = 6.4 Hz, 2H, Ar-H), 7.54 (d, *J* = 6.4 Hz, 2H, Ar-H), 7.53--7.44 (m, 1H, Ar-H), 7.42 (s, 1H, thiazole-H), 7.36 (t, *J* = 7.9 Hz, 1H, Ar-H), 2.60--2.50 (m, 1H,CH), 1.07 (d, *J* = 6.8 Hz, 6H, CH~3~). ^13^C-NMR δ 175.25, 164.03, 148.81, 137.30, 136.94, 134.05, 131.35, 130.62, 128.58, 125.13, 122.56, 120.52, 117.94, 104.63, 35.30, 20.04. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~19~H~19~BrN~3~OS: 416.04267; found: 416.04153.

*N-(4-((4-(4-(Trifluoromethyl)phenyl)thiazol-2-yl)amino)phenyl)isobutyramide* (**A**~33~): white solid; yield 71%; mp: 198.8--199.5 °C; ^1^H-NMR δ 10.23 (s, 1H, NH), 9.73 (s, 1H, NH), 8.24--8.13 (m, 2H, Ar-H), 7.67--7.61 (m, 2H, Ar-H), 7.60--7.56 (m, 2H, Ar-H), 7.55 (d, *J* = 6.4 Hz, 2H, Ar-H), 7.54 (s, 1H, thiazole-H), 2.58--2.50 (m, 1H, CH), 1.07 (d, *J* = 6.8 Hz, 6H, CH~3~). ^13^C-NMR δ 175.32, 164.27, 148.86, 136.96, 135.97, 134.18, 130.40, 130.03, 125.89, 124.45, 122.46, 120.55, 118.04, 105.04, 35.37, 20.11. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~20~H~19~F~3~N~3~OS: 406.11954; found: 406.11868.

*N-(4-(4-(3-(Trifluoromethyl)phenyl)thiazol-2-ylamino)phenyl)isobutyramide* (**A**~34~): yellow solid; yield 81%; mp: 198.8--199.5 °C; ^1^H-NMR δ 10.21 (s, 1H), 9.71 (s, 1H), 8.19 (s, 2H, Ar-H), 7.64 (d, *J* = 6.7 Hz, 2H, Ar-H), 7.58 (m, 2H, Ar-H), 7.53 (s, 1H, thiazole-H), 2.59--2.50 (m, 1H, CH), 1.07 (d, *J* = 6.8 Hz, 6H, CH~3~). ^13^C-NMR δ 175.32, 164.30, 148.88, 136.98, 135.99, 134.20, 130.38, 130.19, 129.98, 125.90, 124.45, 123.73, 122.45, 120.58, 118.07, 105.02, 35.37, 20.10. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~20~H~19~F~3~N~3~OS: 406.11954; found: 406.11826.

*N-(4-((4-(p-Tolyl)thiazol-2-yl)amino)phenyl)isobutyramide* (**A**~35~): yellow solid; yield 73%; mp: 245.2--246.4 °C; ^1^H-NMR δ 10.12 (s, 1H, NH), 9.71 (s, 1H, NH), 7.77 (d, *J* = 8.1 Hz, 2H, Ar-H), 7.58 (d, *J* = 9.1 Hz, 2H, Ar-H), 7.53 (d, *J* = 9.1 Hz, 2H, Ar-H), 7.20 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.18 (s, 1H, thiazole-H), 2.62--2.50 (m, 1H, CH), 2.29 (s, 3H, CH~3~), 1.07 (d, *J* = 6.8 Hz, 6H, CH~3~). ^13^C-NMR δ 175.20, 163.70, 150.60, 137.20, 133.82, 132.41, 129.67, 126.09, 120.49, 117.72, 102.06, 35.28, 21.32, 20.07. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~20~H~22~N~3~OS: 352.14781; found: 352.14685.

*N-(4-((4-Phenylthiazol-2-yl)amino)phenyl)isobutyramide* (**A**~36~): white solid; yield 84%; mp: 239.6--241.0 °C; ^1^H-NMR δ 10.15 (s, 1H, NH), 9.72 (s, 1H, NH), 7.88 (d, *J* = 7.2 Hz, 2H, Ar-H), 7.60 (d, *J* = 9.0 Hz, 2H, Ar-H), 7.55 (d, *J* = 9.0 Hz, 2H, Ar-H), 7.39 (t, *J* = 7.7 Hz, 2H, Ar-H), 7.28 (d, *J* = 7.3 Hz, 1H, Ar-H), 7.26 (s, 1H, Thiazole-H), 2.59--2.50 (m, 1H), 1.07 (d, *J* = 6.8 Hz, 6H, CH~3~). ^13^C-NMR δ 175.23, 150.54, 137.13, 135.04, 133.87, 129.11, 128.00, 126.15, 120.51, 117.76, 102.98, 35.29, 20.06. HRMS (ESI): *m*/*z* \[M + H\]^+^ calculated for C~19~H~20~N~3~OS: 338.13216; found: 338.13101.

3.3. X-ray Diffraction Analysis {#sec3dot3-molecules-25-01772}
-------------------------------

To further confirm the three-dimensional structure of the target compounds, crystals (1.9 mm × 0.5 mm × 1.6 mm) of **A**~4~ ([Figure 2](#molecules-25-01772-f002){ref-type="fig"}) were obtained by slow evaporation and analyzed by X-ray diffraction. Cell dimensions and intensities were measured at 298 K on a Bruker Smart Apex CCD diffractometer with MoKα radiation (*λ* = 0.71073 Å). The structure was solved by direct method with the SHELXS-97 program. The results show that crystals of **A**~4~ is monoclinic system, which is characterized by no higher-order symmetry axis. A total of 2709 reflections were measured, of which 1714 were unique in the range of 2.19 \< θ \< 25.02° (h, −14 to 19; k, −6 to 5; l, −22 to 21). The two benzene rings in the molecule are almost in the same plane. All of the non-H atoms were refined anisotropically by full-matrix least-squares to give the final R = 0.0732 and WR = 0.1820. The completeness of the crystal data is 99.9%. The crystal data of the compound **A**~4~ have been deposited at the Cambridge Crystallographic Data Center under code CCDC 1,975,217 that contains all the above data.

3.4. In Vitro Antibacterial Activity Bioassays {#sec3dot4-molecules-25-01772}
----------------------------------------------

The in vitro antibacterial activity of target compounds against *Xoo*, *Xac* and *Xoc* was evaluated using a turbidimeter test \[[@B26-molecules-25-01772],[@B27-molecules-25-01772]\]. For comparison, the commercial antibacterial agents bismerthiazol and thiodiazole copper was used as positive controls. DMSO in sterile water served as negative control. Nutrient broth medium (NB, 1 g of yeast powder, 3 g of beef extract, 10 g of glucose, 5 g of peptone and 1 L of distilled water, pH 7.0 to 7.2) in tubes was sterilized under high temperature and pressure. The tested compounds were dissolved in 120 μL DMSO then diluted with 0.1% Tween-20 solution, and finally working solution concentrations of 200 and 100 μg/mL were obtained. 1 mL of the solution containing compounds, bismerthiazol and thiadiazole copper was transferred into tubes (15 × 150 mm) containing 4 mL nutrient broth (NB) medium. Approximately 40 μL of activated bacteria was introduced into each tube. Finally, the test tubes were incubated at 28 ± 1 °C with continuous shaking at 180 rpm for 24--48h. The density value (OD~595~) of the solution in the tube was monitored on the microplates when the OD~595~ of the negative control group was 0.6 to 0.8. The inhibition rate was calculated using the following equation: where "CK" represents the density value (OD~595~) of negative control group, and "T" implies the density value (OD~595~) of the treated NB medium. The EC~50~ values against *Xoo*, *Xac* and *Xoc* of the target compounds were tested at five gradient concentrations and computed from analysis using the SPSS 17.0 software (IBM, New York, NY, USA). The experiments were repeated three times for each compound.

3.5. Scanning Electron Microscopy {#sec3dot5-molecules-25-01772}
---------------------------------

The cell surface was observed as previously described \[[@B28-molecules-25-01772]\]. *Xoo* culture (OD~595~ = 1.0) was centrifuged and washed with PBS (pH = 7.2), then resuspended in 1.0 mL of PBS buffer. Then, the cells were treated with compound **A**~1~ for 10 h at 28 °C at concentrations of 50 μg/mL and 100 μg/mL. The untreated sample served as a negative control. Next, the compound solution was removed by washing three times with PBS buffer. The *Xoo* cells were fixed with 2.5% glutaraldehyde at 4 °C overnight and then dehydrated with 70%, and 90% ethanol, respectively.

3.6. Nematicidal Biological Activity In Vitro {#sec3dot6-molecules-25-01772}
---------------------------------------------

The nematicidal activities of the compounds **A**~1~--**A**~36~ against *M. incognita* were tested by a typical assay \[[@B29-molecules-25-01772],[@B30-molecules-25-01772]\]. The tested compounds were dissolved with DMSO and then diluted with 1% Tween-80 solution to prepare 500 and 100 μg/mL solutions. Approximately 200 μL of test solution was added into a 48 well plate. Then a suspension that included approximately 200 living nematodes was added into the above solution. Avermectin was used as positive control. The solution without compound was used as a negative control. All experiments were repeated three times. The mortality of the nematodes was seen under a stereoscopic binocular microscope after 24 and 72 h. The corrected mortality of nematicide was calculated using the following equation:

4. Conclusions {#sec4-molecules-25-01772}
==============

In summary, a series of new *N*-phenylacetamide derivatives containing 4-arylthiazole moieties was designed and synthesized by introducing the thiazole moiety into the scaffolds of *N*-phenylacetamides. The target compounds were evaluated for their in vitro antibacterial activities against *Xoo*, *Xac* and *Xoc*. The bactericidal activity data show that most of the target compounds have moderate inhibitory activities against the above pathogens, among which compounds **A**~1~ and **A**~3~ have good inhibitory effects on *Xoo* and *Xoc*. The cell-rupturing effect of compound **A**~1~ on *Xoo* was studied through SEM analysis. In addition their nematocidal activity was also determined and the compound **A**~23~ exhibited strong toxicity against *M. incognita*, comparable to that of avermectin.

**Sample Availability:** Samples of the compounds **A**~1~--**A**~36~ are available from the authors.

###### 

Click here for additional data file.

^1^H-NMR, ^13^C-NMR and HRMS spectra for the target compounds are available online.
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![Synthetic routes for the target compounds **A**~1~--**A**~36~.](molecules-25-01772-sch001){#molecules-25-01772-sch001}

![SEM images for Xoo after incubated using different concentrations of compound **A**~1~, (**A**) 0 μg/mL; (**B**) 50 μg/mL and (**C**) 100 μg/mL. Scale for A, B and C is 5 μm.](molecules-25-01772-g001){#molecules-25-01772-f001}

![Crystal structure of compound **A**~4~.](molecules-25-01772-g002){#molecules-25-01772-f002}

molecules-25-01772-t001_Table 1

###### 

EC~50~ (µM) values of some target compounds against *Xoo*, *Xac* and *Xoc* ^a^.

  Compound                     EC~50~ (µM) ^c^                
  ---------------------------- ----------------- ------------ ------------
  **A** ~1~                    156.7±7.4         152.0±7.8    250.7±8.0
  **A** ~3~                    260.9±9.0         561.6±6.8    361.4±9.3
  **A** ~4~                    179.2±6.2         281.2±9.4    194.9±8.0
  **A** ~6~                    144.7±3.2         347.3±5.6    248.5±12.1
  **A** ~11~                   512.1±13.4        812.3±11.0   280.6±16.4
  **A** ~13~                   541.4±15.3        660.4±10.1   392.8±6.3
  **A** ~25~                   918.8±19.0        1186±11.9    716.5±19.0
  **Bismerthiazol** ^b^        230.5±7.5         162.7±3.9    254.9±8.2
  **Thiodiazole copper** ^b^   545.2±13.7        476.5±19.9   607.5±3.78

^a^ The statistic analysis was conducted by the ANOVA method under conditions of assumed equal variances (p \> 0.05) and not assumed equal variances (p \< 0.05). ^b^ The commercial antibacterial agents bismerthiazol and thiodiazole-copper were used as positive controls. ^c^ The corresponding regression equation and R value for this EC~50~ are provided in the [Supplementary Materials](#app1-molecules-25-01772){ref-type="app"}.

molecules-25-01772-t002_Table 2

###### 

Mortality (%) of the target compounds against *M. incognita* ^a^.

  Compound             R'/R                    500 μg/mL   100 μg/mL          
  -------------------- ----------------------- ----------- ----------- ------ ------
  **A** ~1~            4-F/CH~3~               26.6        26.9        9.3    9.9
  **A** ~2~            3-F/CH~3~               11.9        13.1        0      5.4
  **A** ~3~            3,4-diF/CH~3~           20.2        23.7        6.4    9.0
  **A** ~4~            4-Cl/CH~3~              14.7        21.8        5.1    5.1
  **A** ~5~            3-Cl/CH~3~              8.7         17.3        0      0
  **A** ~6~            3,4-diCl/CH~3~          11.9        20.5        4.8    7.1
  **A** ~7~            4-Br/CH~3~              14.1        21.2        5.8    8
  **A** ~8~            3-Br/CH3                11.9        14.4        7.1    8.3
  **A** ~9~            4- CF~3~/CH~3~          23.7        29.2        14.1   17.3
  **A** ~10~           3-CF~3~/CH~3~           11.5        17.6        8      8.7
  **A** ~11~           4-CH~3~/CH~3~           14.7        21.8        5.1    5.1
  **A** ~12~           H/CH~3~                 21.2        23.4        3.5    5.4
  **A** ~13~           4-F/CH~2~CH~3~          6.1         11.5        0.6    2.6
  **A** ~14~           3-F/CH~2~CH~3~          6.7         9.9         1.0    3.2
  **A** ~15~           3,4-diF/CH~2~CH~3~      15.1        14.1        2.6    2.9
  **A** ~16~           4-Cl/CH~2~CH~3~         7.4         14.4        3.8    6.7
  **A** ~17~           3-Cl/CH~2~CH~3~         7.4         10.0        1.0    2.3
  **A** ~18~           3,4-diCl/CH~2~CH~3~     21.5        23.1        3.8    4.8
  **A** ~19~           4-Br/CH~2~CH~3~         5.1         2.9         0      0
  **A** ~20~           3-Br/CH~2~CH~3~         15.4        16.7        1.3    1.9
  **A** ~21~           4- CF~3/~CH~2~CH~3~     17.3        18.3        4.2    5.3
  **A** ~22~           3- CF~3~/CH~2~CH~3~     '13.1       15.4        3.8    7.1
  **A** ~23~           4-CH~3~/CH~2~CH~3~      100         100         51.3   53.2
  **A** ~24~           H/CH~2~CH~3~            29.5        30.1        7.7    9.3
  **A** ~25~           4-F/CH(CH~3~)~2~        6.1         11.5        0.6    2.6
  **A** ~26~           3-F/CH(CH3)~2~          6.7         10.0        1.0    5.2
  **A** ~27~           3,4-diF/CH(CH~3~)~2~    15.4        21.2        5.4    7.7
  **A** ~28~           4-Cl/CH(CH~3~)~2~       19.9        20.8        5.8    6.1
  **A** ~29~           3-Cl/CH(CH~3~)~2~       7.4         15.5        0      0
  **A** ~30~           4-CF~3~/CH(CH~3~)~2~    22.1        26          10.3   12.8
  **A** ~31~           3-CF~3~/CH(CH~3~)~2~    17.6        17.6        0      0
  **A** ~32~           3,4-diCl/CH(CH~3~)~2~   17.0        17.3        0      0
  **A** ~33~           4-Br/CH(CH~3~)~2~       16.0        24.7        7.4    8.3
  **A** ~34~           3-Br/CH(CH~3~)~2~       29.8        30.4        9.9    10.9
  **A** ~35~           4-CH~3~/CH(CH~3~)~2~    19.6        20.8        8      9.3
  **A** ~36~           H/CH(CH~3~)~2~          18.6        19.9        8.7    9.3
  **Avermectin** ^b^   100                     100         71.8        79.3   
  **CK** ^c^           0                       0           0           0      

^a^ Averages of three replicates. ^b^ The commercial nematicide avermectin was used for a comparison of activity. ^c^ Control sample.
